



Merck Frosst Canada Ltd. is a research-driven pharmaceutical company discovering, developing and marketing a broad range of innovative medicines and vaccines to improve human health and address unmet medical needs. Based in Montréal, Quebec, Merck Frosst employs over 1,000 people including 225 of the world's leading scientific personnel.

The Merck Frosst Centre for Therapeutic Research is the largest private biomedical research facility in Canada. As a subsidiary of Merck & Co, this facility has a global mandate to discover new therapies for the treatment of infectious diseases. Specifically, there are three key areas of research: treatments that inhibit the replication of the HIV virus; treatments that inhibit the Hepatitis C virus (Merck now has a compound that is in phase two of development); and new antibacterial compounds to deal with antibiotic resistance.

Merck Frosst is one of the top 20 R&D investors in Canada, with an investment of \$110 million in 2007. For more than 100 years, the names Merck and Frosst have been inextricably linked to many advances — in the treatment of infectious diseases, pain and inflammation, for breakthroughs in immunization and vaccines, in the treatment of cardiovascular diseases, in mitigating the effects of glaucoma and osteoporosis and in controlling the symptoms of asthma.

More information about Merck Frosst is available at <http://www.merckfrosst.com>.